NexBio completes Phase I study of influenza drug
The single-dose, escalating Phase I study completed in December 2008 was designed to assess DAS181 safety in healthy subjects. The study drug was well tolerated at all dose
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.